Inactive Instrument

Cell Therapeutics Inc Nasdaq

Equities

US1509346029

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2023	DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	MT
2023	DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	MT

CELL THERAPEUTICS : Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference

January 11, 2010 at 01:35 am EST

MarketScreener.com By

SEATTLE, Jan. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 28th Annual JP Morgan Healthcare Conference in San Francisco. The conference will be held January 11-14, 2010, at the Westin St. Francis. CTI will present on Thursday, January 14, 2010, 2:00 PM Pacific Time. The conference will be webcast live with slides and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.


            28th Annual JP Morgan Healthcare Conference
            CTI Presentation: Thursday, January 14, 2010
     2:00 PM Pacific /5:00 PM Eastern/11:00 PM Central European
       Audio webcast with slides at www.celltherapeutics.com


    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors

SOURCE Cell Therapeutics, Inc.

Latest news about Cell Therapeutics Inc

DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	23-06-26	MT
DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	23-06-26	MT
DRI Healthcare Trust Announces USD 54.8 Million Debt Repayment from CTI Biopharma Corp	23-06-26	CI
Global markets live: Nvidia, IBM, Ford, Pfizer, Lucid Group...	23-06-26
Sobi Wraps Up $1.7 Billion Acquisition of CTI BioPharma	23-06-26	MT
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Global BMI Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Biotechnology Select Industry Index	23-06-26	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index	23-06-26	CI
Swedish Orphan Biovitrum Completes Tender for CTI BioPharma	23-06-25	MT
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of CTI BioPharma Corp. from a group of shareholders.	23-06-25	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Dynamic Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Completeness Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Value Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Growth Index	23-06-23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Growth Index	23-06-23	CI

Chart Cell Therapeutics Inc

Duration

Period

More charts

Company Profile

CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research